Theravance Biopharma, Inc. (TBPH) Return on equity 2016–2025
Theravance Biopharma, Inc. (TBPH) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
35.7%FY2025 · since FY2016: -54.4% → 35.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 35.7% | +67.8 pp |
| FY2024 | -32.1% | -6.2 pp |
| FY2023 | -25.9% | -223.3 pp |
| FY2022 | 197.4% | — |
| FY2017 | -247.8% | -193.4 pp |
| FY2016 | -54.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice